Advancing TCR-based therapies: discovery, analysis, and QC of Ag-specific T cells targeting solid cancers
Oct
17
2024
On demand

Advancing TCR-based therapies: discovery, analysis, and QC of Ag-specific T cells targeting solid cancers

Thursday 08:00 PDT / 11:00 EDT / 16:00 BST / 17:00 CEST
Sponsor
Advancing TCR-based therapies: discovery, analysis, and QC of Ag-specific T cells targeting solid cancers

Dive into essential strategies to successfully tackle TCR discovery and assay development for TCR-based therapies against solid cancers. This webinar will cover the latest approaches to identify tumor-specific TCRs and develop the corresponding robust assays for in-process control, QC, and immune monitoring. We will also introduce how using MHC multimers in flow cytometry can enhance your research and quality assessment processes, providing valuable tools and insights that support your therapeutic development efforts.

  • Understand the latest methodologies for identifying tumor-specific TCRs and their relevance in treating solid cancers
  • Learn best practices for developing precise in-process control and QC assays to ensure the purity and efficacy of TCR-based therapies
  • Discover how MHC multimers can be integrated into flow cytometry and automated workflows for improved TCR identification and QC
Marc Schuster
Marc Schuster
Group Leader, R&D at Miltenyi Biotec
Marc Schuster is a Group Leader in R&D at Miltenyi Biotec with a focus on enhancing analytics in immunology and assay development. With extensive experience in creating immunoassays for both research and pre-clinical drug development, Marc specializes in T cell immunogenicity assays, lab automation, and flow cytometry. He manages research projects adhering to ISO9001 and ISO13485 standards, ensuring high-quality and compliant analytical solutions for advanced therapies.
Marek Wieczorek
Marek Wieczorek
Scientific Director, R&D at Miltenyi Biotec

Marek Wieczorek is Scientific Director of R&D at Miltenyi Biotec, where he is committed to advancing cell and gene therapy analytics. His expertise encompasses antigen-specific T cell analysis, MHC technology, enzyme development, and antibody discovery. Marek earned his PhD from the Leibniz Institute for Molecular Pharmacology and Freie Universität Berlin, where he also completed his postdoctoral research on innovative approaches to improve therapeutic efficacy and precision.

SPEAKERS

Marc Schuster
Marc Schuster
Group Leader, R&D at Miltenyi Biotec
Marek Wieczorek
Marek Wieczorek
Scientific Director, R&D at Miltenyi Biotec

You might also like

Enhancing CAR-T efficacy for targeting lymphoma and solid tumors

Enhancing CAR-T efficacy for targeting lymphoma and solid tumors

Ruchi Patel
3 December
in 12
Days
Register
Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies

Developing off-the-shelf CAR-NK cells targeting CD70: updates from preclinical and early clinical studies

Sunil Acharya
1 August
Watch
Same-section spatial multiomics: a platform for detailed analysis of the solid TME

Same-section spatial multiomics: a platform for detailed analysis of the solid TME

Emily Neil, Ariadna Pascual
27 June
Watch
Comparing activation methods to yield clinical-scale expansion of gamma delta T cells

Comparing activation methods to yield clinical-scale expansion of gamma delta T cells

Chengkang Zhang
24 September
Watch